A Phase 3 interventional study of Tamsulosin Hydrochloride 0.4 mg and Solifenacin Succinate 5 mg in Ureteral Stent-Related Symptom, sponsored by Bir Hospital. Recruiting at 1 site in Nepal. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Bir Hospital · Phase 3, Interventional, and Treatment
A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.
Ureteral stent related symptoms can be a major issue in patient undergoing stent placement after any procedure such as- complains of pain, urinary symptoms, sex related and work related and other symptoms. These symptoms can be alleviated with use of drugs such as Tamsulosin, Solifenacin and Mirabegron. Patient recruited in each arm of the study will have their stent related symptoms scoring done using a validated outcome assessment tool to measure the ureteral stent-related symptoms, Ureteral Stent Symptom Questionnaire (USSQ) on day 1, day 7 and day 14 after the stent placement.
Bir Hospital is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily, to relieve the symptom
Drug: Tamsulosin Hydrochloride 0.4 mg
placement of ureteral stents followed by Tab Solifenacin 5 mg once daily, to relieve the symptom
Drug: Solifenacin Succinate 5 mg
placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily, to relieve the symptom
Drug: Mirabegron 25 mg
placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
Also known as: Cap. Urimax 0.4 mg
placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
Also known as: Tab. Solay 5 mg
placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
Also known as: Tab. Mirasin 25 mg
alleviating Ureteral stent related symptoms
mitigating the ureteric stent related symptoms using structured questionnaire
Time frame: 2 weeks
early removal of ureteral stent
early removal of stent due to stent migration, fever, urosepsis
Time frame: before 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2025, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tamsulosin · Solifenacin · Mirabegron